FDA Commissioner Marty Makary (Photo by Tasos Katopodis/Getty Images for Semafor)

June 17, 2025 01:24 PM EDTUpdated 02:51 PM

FDA unveils one-year pilot to speed some new drugs to market in just one month

Zachary Brennan

Senior Editor

A new FDA pilot program unveiled Tuesday aims to significantly cut drug review times to support what Commissioner Marty Makary deems “national priorities.”

The one …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

FDA unveils one-year pilot to speed some new drugs to market in just one month

Zachary Brennan

Senior Editor

Sign up to read this article for free.

After a quiet year, Xaira unwraps some of its AI research, eyeing a virtual cell

Lilly to bolster gene editing pipeline, buying Verve for up to $1.3B

Dyne pivots on primary endpoint, delays filing for DM1 drug

Orphan drug, PBM changes are excluded from Senate version of Trump tax bill

Lyell’s lymphoma data for recently acquired CAR-T receive lukewarm reception on Wall Street

This company has spent a decade innovating NGS-based companion diagnostics worldwide–what’s next?

FDA un­veils one-year pi­lot to speed some new drugs to mar­ket in just one month

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Af­ter a qui­et year, Xaira un­wraps some of its AI re­search, eye­ing a vir­tu­al cell

Lil­ly to bol­ster gene edit­ing pipeline, buy­ing Verve for up to $1.3B

Dyne piv­ots on pri­ma­ry end­point, de­lays fil­ing for DM1 drug

Or­phan drug, PBM changes are ex­clud­ed from Sen­ate ver­sion of Trump tax bill

Lyell’s lym­phoma da­ta for re­cent­ly ac­quired CAR-T re­ceive luke­warm re­cep­tion on Wall Street

This com­pa­ny has spent a decade in­no­vat­ing NGS-based com­pan­ion di­ag­nos­tics world­wide–what’s next?

FDA unveils one-year pilot to speed some new drugs to market in just one month

After a quiet year, Xaira unwraps some of its AI research, eyeing a virtual cell

Lilly to bolster gene editing pipeline, buying Verve for up to $1.3B

Dyne pivots on primary endpoint, delays filing for DM1 drug

Orphan drug, PBM changes are excluded from Senate version of Trump tax bill

Lyell’s lymphoma data for recently acquired CAR-T receive lukewarm reception on Wall Street

This company has spent a decade innovating NGS-based companion diagnostics worldwide–what’s next?